Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India
pharmafile | March 24, 2016 | News story | Sales and Marketing | AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2
Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India.
Marketed by AstraZeneca as Forxiga, this deal will see this leading diabetes medicine in India, distributed under the brand name, Oxra, by Sun Pharma. Under the terms of the arrangement, both companies will promote, market and distribute dapagliflozin in India under the different brand names.
Following regulatory approval, Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name, Oxramet. AstraZeneca India is currently in the process of seeking similar approval.
Abhay Gandhi, CEO of the Indian business at Sun Pharma, says: “This agreement for dapagliflozin further strengthens our partnership with AstraZeneca India. The addition of this innovative type-2 diabetes treatment bolsters our diabetes portfolio. We believe the extended portfolio will further enhance our service capabilities to offer customers and patients innovative medicines at affordable prices.”
Sanjay Murdeshwar, MD at AstraZeneca India, comments: “Dapagliflozin represents a significant advancement in the treatment of type-2 diabetes and this agreement supports our strategy of working with a local partner to maximise the value from our innovative medicines in a key emerging market. It also ensures a greater number of patients will have access to this important treatment option.”
Sean Murray
Related Content
Study to examine ways of improving diabetes care for younger adults
Researchers at Northumbria University are leading a £1.3m study aimed at helping GP practices improve …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
